Streetbeat News

Stock Prices

SPRY

Analysts have provided mixed ratings for ARS Pharmaceuticals (NASDAQ:SPRY) over the past three months, with a recent average price target of $25.0. The company has shown significant revenue growth and maintains a strong financial position despite challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

TMO

Thermo Fisher Scientific (NYSE:TMO) has significantly outperformed the market over the past 15 years, with an annualized return of 19.03%. A $1000 investment in TMO 15 years ago would be worth $13,025.01 today, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

LOW

Lowe's Companies (NYSE:LOW) has seen a 6.29% increase in short interest, with 9.64 million shares sold short, representing 1.69% of its float. This is below the peer group average of 7.49%. The increase in short interest may indicate bearish sentiment, but it doesn't guarantee a price drop.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

FE

FirstEnergy's short interest has decreased by 4.18%, with 11.14 million shares sold short, representing 2.52% of its float. This is higher than its peers' average of 1.30%. The decrease in short interest may indicate a more bullish sentiment.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

AXON

Axon Enterprise (NASDAQ:AXON) has significantly outperformed the market over the past 5 years, with an annualized return of 41.46%. A $1000 investment in AXON 5 years ago would now be worth $5,729.38. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

RMTI

Rockwell Medical shares rose following the announcement of a significant deal to supply dialysis products for at-home and acute care.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:59 pm

AAPL

Apple has announced the introduction of Apple Intelligence, a new suite of AI features set to launch in October. Despite this announcement, Apple's shares have experienced a downside in trading volume.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:57 pm

AZN

AstraZeneca reported that its drug Datopotamab Deruxtecan showed a numerical overall survival benefit over Docetaxel in the TROPION-Lung01 trial, but it did not reach statistical significance. No overall survival improvement was observed.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:55 pm

TTWO

Martyn Ware, co-founder of Heaven 17, rejected Rockstar Games' $7,500 offer to license the song 'Temptation' for Grand Theft Auto 6, criticizing the offer as undervaluing the song's contribution. Rockstar, a subsidiary of Take-Two Interactive, is known for its impactful game soundtracks.

Portfolio Pulse from Franca Quarneti

September 09, 2024 | 5:54 pm

FOX

FOXA

Seaport Research analyst David Joyce downgraded Fox Corp (NASDAQ:FOX) (NASDAQ:FOXA) from Buy to Neutral due to growth concerns despite a surge in political ad spending. The stock has exceeded the analyst's price target, reflecting political ad enthusiasm, but faces growth challenges.

Portfolio Pulse from Anusuya Lahiri

September 09, 2024 | 5:54 pm